There are currently 1864 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Oral Iron in Children With Chronic Kidney Disease
NCT03991169
Recruiting
This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs. no iron therapy arm for 3 months. The outcomes will include muscle strength, physical activity, and changes in eating behavior, which will be measured at enrollment and at the end of the study period.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
09/27/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Chronic Kidney Insufficiency, Chronic Kidney Diseases
Register for Updates
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT04454528
Recruiting
The primary objective is to determine the feasibility of combining pembrolizumab with a single fraction radiation boost in patients with early/ operable breast cancer. The secondary objectives are to assess clinical response on pre- and post-treatment clinical, imaging, and histology exams, and to assess immune response on pre and post treatment blood and tissue samples by tracking change in Ki67 + CD8 T cells in peripheral blood and in extent of tumor infiltrating lymphocytes. A clinically sign... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT04561362
Recruiting
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C),... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Ovarian Neoplasm, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms
Register for Updates
Vaccine Responses in Cancer
NCT06605625
Recruiting
The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
Gender:
ALL
Ages:
All
Trial Updated:
09/25/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Viral Vaccines
Register for Updates
Parkinson's Disease and Movement Disorders Clinical Database
NCT04997642
Recruiting
The research database contains demographic and family history information, longitudinal information on the clinical symptoms, neuropsychological profile and treatments, stored biological samples, and brain images of patients with Parkinson's disease and related disorders receiving care at the Parkinson's disease and Movement Disorders Center and the Hospital of the University of Pennsylvania.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Parkinson Disease, Parkinson Disease Dementia, Lewy Body Parkinson Disease, Lewy Body Dementia With Behavioral Disturbance
Register for Updates
Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study
NCT06119087
Recruiting
The goal of this clinical trial is to learn how doing mechanical insufflation (MI) using a mechanical insufflator-exsufflator (MI-E) device affects breathing in early amyotrophic lateral sclerosis (ALS). This will be a single-center, single-arm study of MI in 20 patients with ALS at Penn. Based on prior research, we believe that 6-months of MI may slow decline in cough strength, measured as peak cough flow (PCF). Participants will perform MI using a device designed for mechanical insufflation-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Amyotrophic Lateral Sclerosis, Chronic Respiratory Failure, Airway Clearance Impairment, Neuromuscular Diseases
Register for Updates
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
NCT05897788
Recruiting
There is growing recognition of the need for approaches to initiate treatment wherever patients touch the health care system, including the Emergency Department (ED). Most research has focused on initiation of medications for opioid use disorder (MOUDs) in the ED rather than ensuring continued treatment post-discharge. The investigators propose to adapt evidence-based interventions to support patients' complex needs and facilitate continued treatment, rather than discharging them and having them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Opioid Use Disorder, Opioid Dependence With Current Use (Disorder)
Register for Updates
A Phase 3B Study to Evaluate Bone Mineral Density with Long-Term Use of Relugolix Combination Tablet in Women with Uterine Fibroids or Endometriosis
NCT05862272
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
09/24/2024
Locations: Philadelphia, Philadelphia, Pennsylvania +1 locations
Conditions: Uterine Fibroids, Endometriosis
Register for Updates
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
NCT03827694
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
ALL
Ages:
Between 120 days and 21 years
Trial Updated:
09/24/2024
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Register for Updates
TERPS Trial for De Novo Oligometastic Prostate Cancer
NCT05223803
Recruiting
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia, Pennsylvania
Conditions: Prostate Cancer, Oligometastatic Disease
Register for Updates
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
NCT05669833
Recruiting
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/23/2024
Locations: Hospital at the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Psoriatic Arthritis
Register for Updates
Adaptive Radiation for Abdominopelvic Metastases
NCT05880667
Recruiting
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Neoplasm - Soft Tissue Pelvis Malignant Secondary, Malignant Neoplasm of Stomach
Register for Updates